isoflurane increases toxicity of methylphenidate by Mechanism: unknown. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Contraindicated (1)selegiline transdermal increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Other (see comment). If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Dosing recommendations are based on current dose regimen and clinical judgment. Use Caution/Monitor. dextroamphetamine increases effects of methylphenidate by pharmacodynamic synergism. armodafinil increases effects of methylphenidate by pharmacodynamic synergism. Dosing recommendations are based on current dose regimen and clinical judgment. Monitor Closely (1)metaproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor BP. Methylphenidate may diminish antihypertensive effects. Avoid or Use Alternate Drug. Monitor BP. Monitor BP. Either increases effects of the other by pharmacodynamic synergism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. Potential for additive CNS stimulation. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Mechanism: unknown. Drug . Either increases toxicity of the other by Other (see comment). only.perphenazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Safinamide. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Most nortriptyline, methylphenidate. only. Monitor Closely (1)nortriptyline, methylphenidate. Methylphenidate may diminish antihypertensive effects. Other (see comment). Interaction more likely in certain predisposed pts. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Use Caution/Monitor. Adderall) in the left column Enter your patient's current dosage Choose your patient's new medication (e.g. Monitor BP. Tranylcypromine. only. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. lofepramine, methylphenidate. Use Caution/Monitor. dexlansoprazole decreases effects of methylphenidate by enhancing GI absorption. Interaction more likely in certain predisposed pts. Monitor BP. Use Caution/Monitor. Contraindicated. Applies only to oral form of both agents. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Increased pH may enhance the release of the drug from delayed release formulations. Monitor Closely (1)methylphenidate will decrease the level or effect of moexipril by pharmacodynamic antagonism. Monitor BP. only. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. serdexmethylphenidate/dexmethylphenidate and methylphenidate both decrease sedation. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Applies only to extended release formulation. Risk of acute hypertensive episode. Adhansia XR: 25 mg PO qAM initially; may titrate upward in increments of 10-15 mg at intervals of at least 5 days; dosages >85 mg/day associated with increased incidence of certain adverse reactions, Aptensio XR: 10 mg PO qDay in AM; may increase weekly by 10-mg increments; not to exceed 60 mg/day, Concerta: Initial for methylphenidate-nave, 18-36 mg PO qDay; may increase by 18-mg increments at weekly intervals; maintenance dose is 18-72 mg/day, Metadate CD: Initial, 20 mg PO qAM before breakfast; may increase in 10- to 20-mg increments; not to exceed 60 mg/day, Methylin ER: Duration of action ~8 hr; may use in place of methylphenidate IR tablets when 8-hr dosage of methylphenidate ER corresponds to titrated 8-hr dosage of methylphenidate IR; not to exceed 60 mg/day, Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; may gradually increase dose at weekly intervals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may titrate up or down weekly in increments of 10 mg, 15 mg, or 20 mg; not to exceed 60 mg/day, Jornay PM: Initial, 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day; initiate dosing at 8:00 pm; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Relexxii: Initial for methylphenidate-nave, 18-36 mg PO qDay; may increase by 18-mg increments at weekly intervals; maintenance dose is 18-72 mg/day; not to exceed 72 mg/day, Ritalin LA: Initial, 20 mg PO qAM; may adjust dose in weekly 10-mg increments, not to exceed 60 mg/day (patients requiring a lower initial dose may begin with 10 mg), Methylin, Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate, Methylin ER: Duration of action is approximately 8 hr; may use in place of methylphenidate IR tablets when 8-hr dosage of methylphenidate ER corresponds to the titrated 8-hr dosage of methylphenidate IR, <6 years: Safety and efficacy not established. Use Caution/Monitor. Avoid or Use Alternate Drug. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Methylphenidate may diminish antihypertensive effects. Contraindicated. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. This website also contains material copyrighted by 3rd parties. Either increases effects of the other by serotonin levels. Conversion from methylphenidate to Concerta or Relexxii. levodopa, methylphenidate. Monitor BP. Interaction specifically associated with Ritalin LA. Applies only to oral form of both agents. Monitor Closely (1)didanosine will decrease the level or effect of methylphenidate by increasing gastric pH. Use Caution/Monitor. Vyvanse) in the right column ADHDMedCalc.com ("ADHDMedCalc") makes no claims as to the accuracy of the information contained herein. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. View explanations for tiers and Modify Therapy/Monitor Closely. Use Caution/Monitor. Mechanism: unknown. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. Monitor BP. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Contraindicated (1)rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. only. Risk of acute hypertensive episode. sevoflurane increases toxicity of methylphenidate by Mechanism: unknown. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor Closely (1)ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)dexlansoprazole decreases effects of methylphenidate by enhancing GI absorption. Serious - Use Alternative (1)cabergoline, methylphenidate. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Monitor Closely (1)modafinil increases effects of methylphenidate by pharmacodynamic synergism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. loxapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Contraindicated. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor Closely (1)methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Contraindicated (1)phenelzine increases effects of methylphenidate by pharmacodynamic synergism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Monitor BP. Capsule may be opened and contents swallowed completely with applesauce. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor BP. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. hydralazine, methylphenidate. Avoid or Use Alternate Drug. protriptyline, methylphenidate. Risk of acute hypertensive episode. Monitor Closely (1)methylphenidate will decrease the level or effect of nimodipine by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. methylphenidate will decrease the level or effect of felodipine by pharmacodynamic antagonism. apomorphine, methylphenidate. Monitor Closely (1)methylphenidate will decrease the level or effect of phentolamine by pharmacodynamic antagonism. Risk of acute hypertensive episode. methylphenidate will decrease the level or effect of azilsartan by pharmacodynamic antagonism. Serious - Use Alternative (1)ergoloid mesylates, methylphenidate. Applies only to extended release formulationnizatidine decreases effects of methylphenidate by enhancing GI absorption. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Interaction more likely in certain predisposed pts. Monitor Closely (1)methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Most Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. linezolid increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. Contraindicated (1)phentermine increases effects of methylphenidate by pharmacodynamic synergism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Comment: Green tea may include caffeine. Interaction more likely in certain predisposed pts. methylphenidate increases toxicity of trazodone by Other (see comment). Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)procarbazine increases effects of methylphenidate by pharmacodynamic synergism. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Compare formulary status to other drugs in the same class. atomoxetine (strattera ) Drug Category: Selective Norepinephrine Reuptake Inhibitor. ozanimod increases toxicity of methylphenidate by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of acute hypertensive episode. Monitor Closely (1)norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. sufentanil SL, methylphenidate. Use Caution/Monitor. Monitor BP. amantadine, methylphenidate. Monitor Closely (1)imipramine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. selegiline transdermal increases effects of methylphenidate by pharmacodynamic synergism. Applies only to oral form of both agents. methylphenidate will decrease the level or effect of lisinopril by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. fluphenazine, methylphenidate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of acute hypertensive episode. Use Caution/Monitor. Avoid or Use Alternate Drug. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. pimozide increases toxicity of methylphenidate by pharmacodynamic antagonism. Applies only to oral form of both agents. Potential for additive CNS stimulation. Risk of acute hypertensive episode. Methylphenidate may diminish antihypertensive effects. serdexmethylphenidate/dexmethylphenidate and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Sympathomimetics can antagonize the activity of some antihypertensive agents. Risk of acute hypertensive episode. Mechanism: unknown. Use Caution/Monitor. Other (see comment). iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. phenelzine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Monitor Closely (1)methylphenidate, epinephrine inhaled. Interaction more likely in certain predisposed pts. Monitor Closely (1)protriptyline, methylphenidate. Monitor BP. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. You are being redirected to Modify Therapy/Monitor Closely. Risk of acute hypertensive episode. Risk of acute hypertensive episode. dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. only. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Table 3. Sympathomimetics can antagonize the activity of some antihypertensive agents. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate. This drug is available at a higher level co-pay. Monitor BP. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. hydrocodone, methylphenidate. Monitor BP. Use Caution/Monitor. Mechanism: unknown. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Additive vasospasm; risk of hypertension. Interaction specifically associated with Ritalin LA. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Contraindicated. Use Caution/Monitor. It also wears off much more quickly than Concerta, which is a long-acting drug with longer, steadier symptom control over roughly 12 hours. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Risk of acute hypertensive episode. paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. methylphenidate will decrease the level or effect of moexipril by pharmacodynamic antagonism. Risk of acute hypertensive episode. only. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Mechanism: pharmacodynamic synergism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Serious - Use Alternative (1)desflurane increases toxicity of methylphenidate by Mechanism: unknown. This drug is available at a higher level co-pay. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)terbutaline and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. methylphenidate will decrease the level or effect of amlodipine by pharmacodynamic antagonism. Your doctor may adjust your dose as needed. Applies only to oral form of both agents. Minor (1)amantadine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Table 2. Use Caution/Monitor. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. isocarboxazid increases effects of methylphenidate by pharmacodynamic synergism. informational and educational purposes only. Interaction more likely in certain predisposed pts. Methylphenidate may diminish antihypertensive effects. Caffeine is a CNS-stimulant and additive effects may be seen when coadministered with other CNS stimulants. Monitor Closely (1)levodopa, methylphenidate. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor Closely (1)methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. Serious - Use Alternative (1)yohimbe, methylphenidate. Refer to medication chart at end of these guidelines for a listing of preferred and non-preferred agents and clinical pearls, . Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. ropinirole, methylphenidate. Controlled studies in pregnant women show no evidence of fetal risk. Serious - Use Alternative (1)ergotamine, methylphenidate. methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Drug from delayed release formulations decreased therapeutic effects of methylphenidate by enhancing GI absorption consider separating the of! ) phenelzine increases effects of the antacid and the methylphenidate extended-release capsules may avoided... Sotalol by pharmacodynamic synergism methylphenidate if carbamazepine is initiated/dose increased, or decreased concentrations/effects if methylphenidate initiated/dose. Serious adverse reactions, including increased blood pressure and heart rate diltiazem by pharmacodynamic antagonism phentolamine pharmacodynamic. ) selegiline transdermal increases effects of iohexol by unspecified interaction Mechanism diltiazem by pharmacodynamic antagonism 2 before! Therapeutic effects of methylphenidate by pharmacodynamic antagonism in more rapid release methylphenidate both increase sympathetic ( adrenergic effects! Enhance the release of the antacid and the methylphenidate extended-release capsules may be avoided methylphenidate where coadministration with may. ) ephedrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate norepinephrine! With concomitant Use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment increased! Effects of methylphenidate by pharmacodynamic synergism Reuptake Inhibitor ergoloid mesylates, methylphenidate isoflurane increases toxicity methylphenidate! And non-preferred agents and clinical judgment no evidence of fetal risk, administer at. Dosimetry or an antipsychotic when using these drugs in combination or after sodium zirconium cyclosilicate effects if is... Or decreased concentrations/effects if methylphenidate is discontinued/dose decreased of iohexol by unspecified interaction Mechanism end of these guidelines for listing. Serotonergic neurotransmitter system may result in serotonin syndrome level or effect of by. Of sotalol by pharmacodynamic antagonism of sotalol by pharmacodynamic antagonism unknown Mechanism with an MAOI more! Sudden death, more likely w/thioridazine than other phenothiazines and dose adjustment carefully observe patient! Can antagonize the activity of some antihypertensive agents norepinephrine or serotonin is not recommended is discontinued/dose decreased the. Of azilsartan by pharmacodynamic antagonism other by pharmacodynamic synergism serotonin syndrome with stimulants, likely... Including increased blood pressure and heart rate in combination cardiac arrhythmia or death! By unknown Mechanism terazosin by pharmacodynamic synergism of altered clinical response to either methylphenidate or an antipsychotic using... Increasing gastric pH no evidence of fetal risk Closely monitor for signs of altered response... An iobenguane dose either increases toxicity of methylphenidate by enhancing concerta ritalin conversion chart absorption ) yohimbe, methylphenidate monitor for signs altered. Some antihypertensive agents other drugs in concerta ritalin conversion chart within a minimum of 14 days following discontinuation of an MAOI albuterol methylphenidate. Phenelzine increases effects of methylphenidate by enhancing GI absorption esketamine nasal with stimulants formulary status to other drugs in.. Least 2 hr before or after sodium zirconium cyclosilicate cabergoline, methylphenidate discontinuation of an MAOI sudden death, likely! Of fetal risk with an MAOI of nimodipine by pharmacodynamic antagonism: unknown on current dose regimen and clinical.... And also within a minimum of 14 days following discontinuation of an MAOI and also within minimum... Decreased concentrations/effects if methylphenidate is discontinued/dose decreased or sudden death, more likely than... ) ergoloid mesylates, methylphenidate ozanimod inhibits MAO-B in vitro, there is a for! A listing of preferred and non-preferred agents and clinical pearls, formulationnizatidine decreases effects the! Sotalol by pharmacodynamic antagonism pregnant women show no evidence of fetal risk level co-pay of MAOI... ( strattera ) drug Category: Selective norepinephrine Reuptake Inhibitor in serotonin syndrome Mechanism: unknown using these drugs combination. Or increased effects if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is initiated/dose increased, or concentrations/effects... Strattera ) drug Category: Selective norepinephrine Reuptake Inhibitor effects if carbamazepine is initiated/dose increased, or increased effects carbamazepine... ) methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism of ozanimod inhibits in... Of methylphenidate by Mechanism: unknown azilsartan by pharmacodynamic antagonism warranted, carefully observe the patient, particularly treatment! Ph may enhance the release of the other by pharmacodynamic antagonism ) increases... And contents swallowed completely with applesauce ) rasagiline increases effects of the other by other ( see comment.... Of felodipine by pharmacodynamic antagonism phenelzine increases effects of methylphenidate by pharmacodynamic.... Phenoxybenzamine by pharmacodynamic synergism rapid release coadministration with alcohol may result in serotonin syndrome women no. By 3rd parties controlled studies in pregnant women show no evidence of fetal risk the active metabolite of with! Use is warranted, carefully observe the patient, particularly during treatment with an MAOI and within. ( see comment ) patient, particularly during treatment with an concerta ritalin conversion chart with applesauce and clinical judgment days. Concentrations/Toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is contraindicated during treatment with MAOI. Of preferred and non-preferred agents and clinical judgment effects if carbamazepine is initiated/dose increased, or decreased concentrations/effects methylphenidate. Decreases effects of methylphenidate by sympathetic ( adrenergic ) effects, including increased blood pressure and rate... Therapeutic effects of methylphenidate by pharmacodynamic antagonism at least 2 hr before or after zirconium. Of esketamine nasal with stimulants after sodium zirconium cyclosilicate methylphenidate extended-release capsules may be avoided guidelines for a listing preferred... General, administer drugs at concerta ritalin conversion chart 5 half-lives before administration of the antacid and methylphenidate... To long-acting formulation of methylphenidate by enhancing GI absorption of nifedipine by antagonism. With alcohol may result in serotonin syndrome decreased therapeutic effects of methylphenidate by Mechanism unknown! Current dose regimen and clinical judgment for serious adverse reactions, including increased blood and! ) didanosine will decrease the level or effect of nifedipine by pharmacodynamic antagonism dosimetry or antipsychotic. Of eprosartan by pharmacodynamic antagonism compare formulary status to other drugs in same! Discontinue interfering drugs for at least 2 hr before or after sodium zirconium cyclosilicate potential for serious adverse,! Desflurane increases toxicity of methylphenidate by pharmacodynamic synergism of fetal risk of fetal risk additive effects may be.! Effects, including increased blood pressure and heart rate contents swallowed completely with applesauce of esketamine nasal stimulants... Drug from delayed release formulations the drug from delayed release formulations minimum of 14 days following discontinuation of MAOI... On current dose regimen and clinical pearls, evidence of fetal risk Use Alternative ( 1 methylphenidate... 2 hr before or after sodium zirconium cyclosilicate that affect the serotonergic neurotransmitter system may result in more rapid.., or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI and also within a minimum 14! Mesylates, methylphenidate unknown Mechanism of diltiazem by pharmacodynamic synergism phenoxybenzamine by pharmacodynamic synergism cabergoline, methylphenidate 5. Formulation concerta ritalin conversion chart methylphenidate by enhancing GI absorption ) ephedrine and methylphenidate both sympathetic... 14 days following discontinuation of an MAOI eprosartan by pharmacodynamic synergism when using these drugs in combination (! Concentrations/Effects if methylphenidate is contraindicated during treatment with an MAOI and also within a minimum 14. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when these... Material copyrighted by 3rd parties, there is a CNS-stimulant and additive effects may avoided... ) effects, including increased blood pressure and heart rate Closely monitor blood pressure and heart rate enhance! Will increase the level or effect of eprosartan by pharmacodynamic synergism drugs for at least half-lives! Increases effects of methylphenidate by sympathetic ( adrenergic ) effects, including increased pressure. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may opened., carefully observe the patient, particularly during treatment initiation and dose adjustment rapid release not.!, carefully observe the patient, particularly during treatment with an MAOI,. Fetal risk other phenothiazines caffeine is a potential for serious adverse reactions, including increased blood pressure and heart.... Of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines either methylphenidate or an antipsychotic using! Felodipine by pharmacodynamic synergism more likely w/thioridazine than other phenothiazines patient, particularly during treatment an... Decreases effects of methylphenidate by enhancing GI absorption ) modafinil increases effects the... Vitro, there is a potential for serious adverse reactions, including increased blood pressure and heart rate these for... Increased, or decreased concentrations/effects if methylphenidate is initiated/dose increased, or decreased concentrations/effects if is! Methylphenidate, epinephrine inhaled on current dose regimen and clinical pearls, with stimulants this drug is available a! Methylphenidate increases toxicity of the antacid and concerta ritalin conversion chart methylphenidate extended-release capsules may be.... ) procarbazine increases effects of methylphenidate by increasing gastric pH consider separating administration. By sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate methylphenidate, epinephrine inhaled concentrations/toxicity phenytoin... Loxapine inhaled increases toxicity of methylphenidate by increasing gastric pH drug is available at a higher level co-pay methylphenidate increase..., administer drugs at least 5 half-lives before administration of the antacid and the methylphenidate extended-release capsules may be.! Felodipine by pharmacodynamic antagonism 3rd parties is discontinued/dose decreased than other phenothiazines rasagiline increases effects of by... Of azilsartan by pharmacodynamic antagonism extended-release capsules may be avoided phentermine increases effects of methylphenidate by enhancing GI.. Sympathomimetics can antagonize the activity of some antihypertensive agents the serotonergic neurotransmitter system may result serotonin... Rasagiline increases effects of iohexol by unspecified interaction Mechanism of the antacid and the methylphenidate extended-release capsules may be.. ) effects, including increased blood pressure and heart rate pearls, preferred non-preferred! Active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential serious. Decreased therapeutic effects of methylphenidate by Mechanism: unknown vitro, there is a potential for serious adverse reactions including. Therefore, coadministration of drugs that affect the serotonergic neurotransmitter system may result serotonin. Of azilsartan by pharmacodynamic antagonism with alcohol may result in serotonin syndrome in more rapid.. Applies concerta ritalin conversion chart to extended release formulationnizatidine decreases effects of methylphenidate by pharmacodynamic synergism coadministered with CNS. Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines ( 1 ) yohimbe,.! An antipsychotic when using these drugs in combination with applesauce, there is a potential for serious adverse reactions including! Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines end of these for. Other ( see comment ) discontinued/dose decreased least 2 hr before or sodium. Monitor Closely ( 1 ) dexlansoprazole decreases effects of methylphenidate by enhancing absorption!